DEUTERIUM-ENRICHED EZETIMIBE

1 . A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 —R 21 are independently selected from H and D; and the abundance of deuterium in R 1 —R 21 is at least 5%.

2 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 —R 21 is selected from at least 5%, at least 10%, at least 14%, at least 19%, at least 24%, at least 29%, at least 33%, at least 38%, at least 43%, at least 48%, at least 52%, (k) at least 57%, at least 62%, at least 67%, at least 71%, at least 76%, at least 81%, at least 86%, at least 90%, at least 95%, and 100%.

3 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 —R 2 is selected from at least 50% and 100%.

4 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 3 —R 6 is selected from at least 25%, at least 50%, at least 75%, and 100%.

5 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 7 —R 8 is selected from at least 50% and 100%.

6 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 9 —R 13 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

7 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 14 —R 17 is selected from at least 25%, at least 50%, at least 75%, and 100%.

8 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 18 —R 21 is selected from at least 25%, at least 50%, at least 75%, and 100%.

9 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 1-7 of Table 1:

10 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 8-14 of Table 2:

11 . An isolated deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 —R 21 are independently selected from H and D; and

the abundance of deuterium in R 1 —R 21 is at least 5%.

12 . An isolated deuterium-enriched compound of claim 11 , wherein the abundance of deuterium in R 1 —R 21 is selected from at least 5%, at least 10%, at least 14%, at least 19%, at least 24%, at least 29%, at least 33%, at least 38%, at least 43%, at least 48%, at least 52%, (k) at least 57%, at least 62%, at least 67%, at least 71%, at least 76%, at least 81%, at least 86%, at least 90%, at least 95%, and 100%.

13 . An isolated deuterium-enriched compound of claim 11 , wherein the abundance of deuterium in R 1 —R 2 is selected from at least 50% and 100%.

14 . An isolated deuterium-enriched compound of claim 11 , wherein the abundance of deuterium in R 3 —R 6 is selected from at least 25%, at least 50%, at least 75%, and 100%.

15 . An isolated deuterium-enriched compound of claim 11 , wherein the abundance of deuterium in R 7 —R 9 is selected from at least 50% and 100%.

16 . An isolated deuterium-enriched compound of claim 11 , wherein the abundance of deuterium in R 9 —R 13 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

17 . An isolated deuterium-enriched compound of claim 11 , wherein the abundance of deuterium in R 14 —R 17 is selected from at least 25%, at least 50%, at least 75%, and 100%.

18 . An isolated deuterium-enriched compound of claim 11 , wherein the abundance of deuterium in R 1g —R 21 is selected from at least 25%, at least 50%, at least 75%, and 100%.

19 . An isolated deuterium-enriched compound of claim 11 , wherein the compound is selected from compounds I-7 of Table 1:

20 . An isolated deuterium-enriched compound of claim 11 , wherein the compound is selected from compounds 8-14 of Table 2:

21 . A mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 —R 21 are independently selected from H and D; and the abundance of deuterium in R 1 —R 21 is at least 5%.

22 . A mixture of deuterium-enriched compound of claim 21 , wherein the abundance of deuterium in R 1 —R 21 is selected from at least 5%, at least 10%, at least 14%, at least 19%, at least 24%, at least 29%, at least 33%, at least 38%, at least 43%, at least 48%, at least 52%, (k) at least 57%, at least 62%, at least 67%, at least 71%, at least 76%, at least 81%, at least 86%, at least 90%, at least 95%, and 100%.

23 . A mixture of deuterium-enriched compound of claim 21 , wherein the abundance of deuterium in R 1 —R 2 is selected from at least 50% and 100%.

24 . A mixture of deuterium-enriched compound of claim 21 , wherein the abundance of deuterium in R 3 —R 6 is selected from at least 25%, at least 50%, at least 75%, and 100%.

25 . A mixture of deuterium-enriched compound of claim 21 , wherein the abundance of deuterium in R 7 —R 8 is selected from at least 50% and 100%.

26 . A mixture of deuterium-enriched compound of claim 21 , wherein the abundance of deuterium in R 9 —R 13 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

27 . A mixture of deuterium-enriched compound of claim 21 , wherein the abundance of deuterium in R 14 —R 17 is selected from at least 25%, at least 50%, at least 75%, and 100%.

28 . A mixture of deuterium-enriched compound of claim 21 , wherein the abundance of deuterium in R 18 —R 21 is selected from at least 25%, at least 50%, at least 75%, and 100%.

29 . A mixture of deuterium-enriched compound of claim 21 , wherein the compound is selected from compounds I-7 of Table 1:

30 . A mixture of deuterium-enriched compound of claim 21 , wherein the compound is selected from compounds 8-14 of Table 2:

31 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

32 . A method for treating a disease selected from hypercholesterolaemia and/or phytosterolaemia comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.